A global perspective on transitioning from pediatric to adult care in epilepsy

Danielle M Andrade1,2,3,4, Nathalie Jetté5, Ilakkiah Chandran1,4

  • 1Adult Genetic Epilepsy (AGE) Program, University of Toronto, Toronto, Ontario, Canada.

Epilepsia
|October 23, 2025
PubMed

Insights

Epilepsy transition care is underdeveloped globally, with few structured programs, especially in low-resource areas. Improving training and infrastructure is vital for equitable patient transitions.

Area of Science:

  • Neurology
  • Healthcare Management
  • Global Health

Background:

  • Transition planning for adolescents with epilepsy is critical for continuous care but lacks defined global practices.
  • The International League Against Epilepsy Transition Task Force (ILAE TTF) initiated a study to assess worldwide transition practices, barriers, and provider insights.

Purpose of the Study:

  • To evaluate global practices in transitioning epilepsy patients from pediatric to adult healthcare.
  • To identify barriers and gather recommendations for improving epilepsy transition care worldwide.

Main Methods:

  • A cross-sectional, web-based survey was distributed in eight languages to healthcare professionals involved in epilepsy care.
  • Data from 316 neurologists across 58 countries were analyzed using descriptive statistics and logistic regression.

Main Results:

  • Only 9% of participants reported structured transition programs; significantly fewer in the Global South.
  • Key barriers included lack of funding, inadequate training, and adult neurologists' unfamiliarity with childhood epilepsies.
  • Major patient educational gaps identified in vocational guidance, reproductive health, and driving.

Conclusions:

  • Epilepsy transition practices are fragmented globally, particularly in low-resource settings.
  • Enhanced training, clinical infrastructure, and policy coordination are essential for effective and equitable transitions.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
191
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
209
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
241
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
251
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
185